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Abstract
Biotin is an essential growth factor found in all living cells. It functions as a
cofactor for a group of coenzymes that catalyze transcarboxylation, decarboxylation, and
carboxylation reactions. Acetyl CoA carboxylase catalyzes the first committed and
regulated step in fatty acid synthesis in which malonyl CoA is the product. The biotindependent enzyme is found in all animals, plants, and bacteria. We studied the kinetic
and structural aspects of acetyl CoA carboxylase, and in 1999 we reported the bioactivity
and total synthesis of a unique first generation biotin-derived inhibitor of acetyl CoA
carboxylase, 1(BP1). Kinetic studies on the activity of E. coli biotin carboxylase yielded
an inhibition constant of 8.4±1 mM. Since that time, we have improved the yield and
purification of 1. Currently, we are designing multisubstrate analogs which involve the
attachment of adenosine moieties at the 1-N of biotin. We reason that these compounds
will have a greater affinity for acetyl CoA carboxylase. In addition, we are synthesizing
biotin derivatives for their study in three main areas: (1) understanding the mechanism of
biotin carboxylase and acetyl CoA carboxylase for the development of new therapeutic
agents, (2) screening for ribozyme activity to support the “RNA World” hypothesis, and
(3) investigation of chiral cationic micelles for analytical separations.

xii

Chapter One
Introduction
1.1 Biotin-dependent Carboxylases
Biotin, or vitamin H, is an essential component of all living cells. It was first
isolated as a growth factor for yeast in 1936 in its methyl ester form.1 The proposed
structure for (+)-biotin (Figure 1) was confirmed by the first total synthesis by Merck.2
Structurally, the molecule consists of a bicyclic ring system whose mirror symmetry is
broken by a valeric acid side chain. The top ring of the bicyclic system is a ureido ring,
and the bottom ring, containing sulfur, is a tetrahydrothiophene (or thiophane) ring.
Biotin further possesses three contiguous stereocenters on the thiophane ring in the all-cis
configuration.

1'

HN
H

O 3'
NH
H
S
(+) - biotin

OH
O

Figure 1: Structure of (+)-biotin

The natural sources of biotin are the pancreas, liver, kidney, yeast, and egg yolk.
Low levels of biotin in poultry and red meat cause a series of symptoms.

These

deficiencies are corrected by using biotin as a feed additive. Biotin functions as a cofactor
in carboxylation, decarboxylation, and transcarboxylation reactions related to
biochemical processes such as glucogenesis and fatty acid synthesis.3 Because of its

1

fundamental and commercial importance biotin has attracted the attention of both
academic and industrial biologists and chemists.
Acetyl CoA carboxylase (ACC) carries out the first committed and regulated step
in fatty acid biosynthesis. The biotin-containing enzyme catalyzes the ATP-dependent
formation of malonyl CoA from acetyl CoA and bicarbonate.4 Acetyl CoA carboxylase
is found in all animals, plants, and bacteria. Biotin-dependent enzymes, such as ACC, in
general have three domains: the biotin carboxyl carrier protein, biotin carboxylase, and
carboxytransferase (Figure 2). Depending on the organism, these components may occur
as separate subunits. For example, pyruvate carboxylase has the biotinyl and
transcarboxylase domains on one subunit and the biotin carboxylase on another, whereas
in the carboxylases from some yeast, insects, vertebrates, and bacteria, such as
Eschericha coli, all three components are found on one polypeptide chain.

O
PO3-2

O

Biotin
Carboxylase
Subunit

Biotin
Carboxylase
Subunit

OH
N

O

S

N
H

Biotin
Carrier
Protein

O
N
H

H
N
O
S

Biotin
Carrier
Protein

H
N
O

S

N
O

CoA

O

S

O-

CoA

O-

Carboxytransferase
Subunit

Carboxytransferase
Subunit

Figure 2: The three domains of biotin-dependent enzymes.
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Biotin-dependent carboxylases function by means of a two-step reaction
sequence shown in Scheme 1.5 Biotin is covalently attached to the carboxyl carrier
protein via an amide bond between the valeric acid side chain of biotin and the ∈ group
of a lysine residue. In the first half-reaction, Knowles describes the carboxylation of
biotin whereby there is an ATP-driven attachment of carbon dioxide from bicarbonate at
the 1’-N position of the biotin cyclic urea ring through the catalysis of biotin
carboxylase.6 A carboxyphosphate intermediate is involved, and 1’-N-carboxybiotin is
generated stepwise. In the second half reaction, the activity of carboxytransferase allows
for the transfer of carbon dioxide from carboxybiotin to the acceptor, acetyl CoA,
forming the product of fatty acid synthesis, malonyl CoA.

(1) Enzyme-biotin + Mg2+ - ATP + HCO3-

Mg2+

(2) Enzyme-biotin-CO2- + acceptor

-

Enzyme-biotin-CO2 + Mg

2+

-ADP + Pi

acceptor-CO2- + Enzyme-biotin

Scheme 1: The two-step reaction used by all biotin-dependent enzymes.

Since Knowles’s review in 1989,6 there have been several reviews on biotindependent enzymes which describe the progress towards elucidating their mechanism of
action.7,8,9 For several years, Strongin and Waldrop have collaboratively studied the
structural and mechanistic aspects of the biotin carboxylase subunit of acetyl CoA
carboxylase. In 1999, they reported the total synthesis and bioactivity of the first biotinderived inhibitor of biotin carboxylase, compound 1, or BP1 (Figure 3).10,11 This thesis
focuses on the efforts currently being made to improve the yield and purification of the

3

BP1 analog as well as the synthesis of new biotin derivatives for their study in three
main areas: (1) understanding the mechanism of biotin carboxylase for the development
of new therapeutic agents, (2) screening for ribozyme activity to support the “RNA
World” hypothesis, and (3) investigation of the first chiral cationic micelles.

O
O
HO P
O
OH
HO

O
HO P
HO

carboxyphosphate

O

O
N

NH
H

H
S

1

OH
O

Figure 3: Compound 1 embodies a stable analog of the naturally occurring
carboxyphosphate intermediate involved in biotin-mediated CO2.
1.2 Background
A number of proposed mechanisms for the carboxylation of biotin in reaction 1
(Scheme 3) have been considered. These included the initial formation of a
phosphobiotin intermediate which then reacts in a concerted reaction with bicarbonate to
form carboxybiotin and Pi (Scheme 2a). Another mechanism involved formation of
carboxyphosphate. Biotin is then directly carboxylated via a nucleophilic attack of the
1-N of biotin on the carboxyl carbon. Carboxyphosphate can also decarboxylate to form
the strong electrophile CO2, which is then the carboxylating species (Scheme 2b).
Knowles6 concluded that the most likely route to carboxybiotin was via a
carboxyphosphate intermediate from ATP and bicarbonate. To date, however, there has
not been a direct demonstration of the existence of carboxyphosphate.13, 14
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a.
-

O
HO C
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HOPO32-O2C N

NH

NH
S

S

carboxybiotin

phosphobiotin
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-

O

O

O

C

P

O

OO

-

N

O

-

-
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O
O C

N

O

HOPO32-O2C N

NH

NH

O
PO32- S

S
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S

carboxybiotin
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E Lys NH3

E Lys NH2

Cys S-

Cys S H

H3
E Lys N

O

-

O

Cys SH
H

N

NH
S

O

N

NH

C
O

S

E Lys NH3
Cys SH O
C N
O

O
NH
S

Scheme 2: Mechanisms a and b are proposed mechanisms for the carboxylation of
the 1’-N of biotin to form carboxybiotin. Mechanism c suggests that a cysteinelysine base pair form the base and conjugate acid involved in the enolation of biotin.
The favored route to carboxylation of biotin from carboxyphosphate involves
initial proton abstraction from the 1’-N of biotin by an enzymic base, resulting in the
formation of the enolate which can attack the carboxylating species. Attwood and
coworkers9 proposed that a cysteine-lysine ion pair are involved in the conversion of
biotin from the ureido to eneamine form (Scheme 2c). The lysine would deprotonate
cysteine to form a thiolate anion, which would remove the 1’-N proton from biotin. The
positively charged ∈-NH3+ of lysine stabilizes the enolate oxygen of biotin. This would
result in the enolate of biotin containing a very nucleophilic 1’-N, ready to attack the
5

carboxylating species. On the contrary, a recent theoretical study by Grant15 has raised
the possibility of there being concerted carboxylation and deprotonation of biotin in
reaction 1 (Scheme 1). He also proposed a mechanistic role for sulfur on the thiophane
ring of biotin. Grant has calculated that a twisted conformation of the bicyclic ring
structure can lead to orbital overlap between the sulfur and the ureido group, increasing
the nucleophilic character of the 1’-N on biotin.
Although many questions remain to be answered, many advances have been made
relating to the study of the catalytic mechanism of biotin carboxylase as a result of the
determination of the three–dimensional structure of biotin carboxylase by X-ray
crystallography.15 High-resolution crystallographic structures of the biotin carboxylase
subunit of acetyl CoA carboxylase co-crystallized with substrates would be an important
breakthrough.
It is known from recent studies reported by Blanchard and Waldrop that biotin has
a low affinity (Km =134 mM) for the enzyme acetyl CoA carboxylase in contrast to the
Km values of 0.7 mM and 0.05 mM for bicarbonate and ATP, respectively.16 Therefore,
one possible way to overcome low affinity of biotin for the enzyme is to synthesize a
multisubstrate analog linking biotin to tighter binding substrates like bicarbonate and
ATP as shown in Figure 4. The design and synthesis of 1 was the direct result of this
reasoning.
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NH2
N

N

N

N

O

O
O
O
O P O P O P OH
HO HO HO

O

-

O
O-

O

OH OH

HN
H

NH
H
S

ATP

bicarbonate

OH
O

(+) - biotin

Figure 4: Substrates with varying affinities for acetyl CoA carboxylase.

The activity of biotin carboxylase was measured in the absence and presence of
increasing amounts of 1. As the concentration of the analog increased the initial velocity
of biotin carboxylase from E.coli decreased. Fitting the data to the equation for linear
competitive inhibition by linear regression analysis yielded a slope inhibition constant of
8.4±1mM. While this is a modest degree of inhibition, placing a phosphonoacetic acid
moiety at the 1-N of biotin allows BP1 to bind 10 times more tightly to the enzyme than
free biotin.
NH2
N

N
N

N
O

O
O P
HO

O

O
N

NH
H

H

OH OH

S

OH
O

Figure 5: Proposed multisubstrate inhibitor(s) of biotin carboxylase.

The new biotin derivatives we are currently synthesizing include multisubstrate
inhibitors (Figure 5) that will incorporate AMP, ADP, and ATP, respectively. The
7

inhibition of these compounds will be compared to that of the patented BP1 analog. We
hypothesize that these derivatives will have a significantly lower inhibition constant than
the first-generation analog.
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Chapter Two
Carboxyphosphate Reaction Intermediate Analog
2.1 Introduction
There has been growing interest in our reaction intermediate analog BP1 since its
total synthesis and inhibitory effect on biotin carboxylase were reported in 1999.10,11 In
several collaborative efforts, we have studied BP1 as both an antiobesity and anti-HIV
therapeutic agent. In addition, compound 1 has been utilized as a substrate in the
screening of ribozyme activity to support the “RNA World” hypothesis.
The total synthesis of 1, (Scheme 3) described previously by Amspacher,10 begins
with the protection of (+)-biotin as the corresponding ester in 95% yield via reaction with
benzyl alcohol, DCC, and catalytic amounts of HOBT and DMAP. Biotin benzyl ester 2
is reacted with chloroacetylchloride to furnish compound 3 in 98% yield. Compound 3
then undergoes an Arbuzov reaction with P(OEt)3 at 100°C to obtain phosphonate ester 4
in 88% yield.

Hydrolysis of 4, promoted by TMSBr, provides the corresponding

phosphonic acid in 72% yield. Subsequent saponification of 5 with LiOH affords target
compound 1 in 59% yield and an overall 22% yield.
The synthesis of BP1 is straightforward and the yields of all intermediates are
excellent. The saponification step, however, is not as efficient when compared to the
preceding four steps in the synthesis. I thus optimized the reaction conditions as well as
the purification methods to improve the yield of the saponification reaction before
submitting the BP1 analog to our collaborators for utilization in biological assays.
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Scheme 3: The preparation of 1 from (+)-biotin.

2.2 Improved Yield of Carboxyphosphate Reaction Intermediate Analog
We first attempted the cleavage of the benzyl ester on phosphonic acid 5 by more
classical synthetic organic means, such as hydrogenation. Although it is a known fact
that sulfur poisons palladium catalysts, successful hydrogenation of sulfur-containing
compounds has been previously reported.17 Compound 5 was reacted with 10% Pd/C in
THF under H2 (50 psi) overnight; the target compound was not obtained. Further work
may be necessary. We meantime concluded reaction with LiOH followed by immediate
neutralization and lyophilization of the reaction mixture were the optimum conditions.

10

The carboxphosphate reaction intermediate analog had only been synthesized
previously on milligram scale. In my efforts to scale up the saponification step, the pH
sensitivity of BP1 as well as the polarity of starting material and final product became
challenging issues.

The time required for the conversion of compound 5 to 1 is

approximately 2 hrs ± 20 minutes. I discovered this 20-minute window made a significant
difference in the yield of BP1 obtained. Due to the polarity of the reactant and desired
product, the exact time at which the reaction was complete was difficult to determine by
thin layer chromatograghy (TLC). Stopping the reaction prematurely resulted in a polar
mixture of starting material and product, which was seemingly impossible to separate.
Even with polar solvent systems, such as 9:1 CHCl3: MeOH, 5% v/v Et3N, the retention
times of the two compounds were indistinguishable. Removal of the phosphonic acid side
chain at the C-N bond to afford biotin results when the reaction is allowed to exceed the
time required for maximum conversion of phosphonic acid 5 to BP1.
I resolved these synthetic issues by carefully monitoring the saponification
reaction by 1H NMR. A small aliquot was taken from the reaction flask every 20 minutes
and evaporated. The concentrate was dissolved in D2O, and a 1H NMR was generated on
a high-resolution spectrometer. I monitored the change in the chemical shift of the valeric
acid α protons and stopped the reaction when the integral ratio of product to starting
material was greatest. Because the reaction proceeds towards the production of biotin as
long as the reaction mixture is basic, the solution was immediately neutralized then
lyophilized. In previous instances, the water was removed by evaporation in vacuo at
high temperatures, contributing to partial decomposition of the desired product. By
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making these minor yet necessary changes, I increased the yield of BP1 from 59% to
68%.
2.3 HPLC Isolation of Carboxyphospate Reaction Intermediate Analog
Target compound BP1 was formerly purified by recrystallization, which often
affords a diminished yield of the desired compound due to the high temperatures
employed. Because BP1 is unstable at elevated temperatures, an alternative purification
method was needed. We anticipated isolation by HPLC coupled with the modified
saponification experimental procedure would further increase the yield of reaction
intermediate analog 1.
The complexes of biotin with streptavidin and its structural homologue avidin are
known to be the strongest ligand-protein complexes,18,19 with measured binding constants
of 1.7×105 and 2.5×1013, respectively.18-21 The high affinity binding of these two systems
has found many applications in affinity chromatograghy,22 and it is most commonly the
technique of choice for the purification of biotin derivatives. Contrarily, we decided to
try another HPLC method for the isolation of compound 1-reverse phase
chromatography. As simple as the concept seemed, to our knowledge, isolation of biotin
or biotinylated compounds had not been achieved without the employment of an affinity
column.
With the aid of my colleague Jorge Escobedo, reverse phase analysis of BP1, was
performed with H2O and MeOH. Composition of the eluent was isocratically changed
from 100% H2O for 10 minutes to 100% MeOH over a 30-minute time period. The UV
detector was set at 205 nm and 240 nm. The chromatogram generated (Figure 6) three
peaks of interest, with retention times of 9.17, 11.83, and 41.0 minutes, respectively.
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These fractions were immediately lyophilized upon collection. The fraction at 11.83
minutes was confirmed by 1H NMR to be biotin. Therefore, we believed some degree of
decomposition occurred. Interestingly, the sample from which the fractions were isolated
was allowed to sit at basic pH overnight before being injected. A proton NMR of the BP1
standard from which the sample was prepared, however, contained all significant peaks,
specifically the phosphonic acid α protons at ≈2.5 ppm. In addition, the

31

P NMR

showed one single peak at approximately 15 ppm. This result supported our original
hypothesis that the basicity of the solution causes removal of the phosphonic acid side
chain. The NMR spectrum of the eluent at 9.17 minutes was also identified as a
decomposed BP1 product, but to a lesser degree than 11.83 minute eluent. In contrast to
spectrum of the fraction identified prove to biotin; the α protons were observed, but they
were broad and diminished in size and integral ratio. The peak at 41.0 minutes was not
the desired product or any significant by-product, so no further characterization was
performed.

Figure 6: Chromatogram of BP1 aqueous solution (pH 8) allowed to sit overnight.
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A series of experiments were performed to obtain conclusive evidence of whether
the pH was affecting the separation of BP1 or merely the appearance of the 1H NMR
spectrum generated. Three BP1 aqueous solutions of varying pH’s were prepared. The
initial pH of each solution was approximately 9. Using a 1.0M solution of HCl, the pH
was adjusted to 5.5, 6.0, and neutral pH, respectively.

The samples were injected

immediately upon preparation. Using the same gradient conditions described above, the
best resolved chromatogram was obtained from analysis of the pH 6 solution. This
chromatogram is shown in Figure 7. For this particular case, the peaks of interest were at
9.0, 10.5, and 16.8 minutes. The 9.0 minute peak was determined to be insignificant, or a
“ghost peak”.

The NMR sprectrum of the 10.5 minute fraction beared the closest

resemblance to that of BP1, with the exception of the two characteristic α protons. The
spectrum of the 16.8 minute peak overlayed with that of biotin with the exception of the
amide protons, which have a chemical shift of approximately 6.5 ppm. Thus I could not
yet conclude that BP1 was successfully isolated by HPLC.

Figure 7: Chromatogram of BP1 aqueous solution (pH 6).
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A 1H NMR of the standard BP1 solution (pH 8) was taken. The alpha protons
were visible at the correct chemical shift and integrated properly. The pH of the same
sample was adjusted to 6; then another spectrum was generated. The two peaks of
interest were no longer present. In fact, the spectrum overlayed with that of the 10.5
minute fraction isolated from the pH 6.0 solution (Figure 7). The sample pH was then
elevated back to ≈8.5, using saturated NaHCO3. A final NMR was obtained, which was
analogous to the spectra of the BP1 standard. Hence, isolation of BP1 by reverse phase
HPLC was accomplished. I concluded that the absence or presence of the α-protons in
the NMR spectrum is the result of an ionization effect.
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Chapter Three
Bioactivity
3.1 Effect of CABI on Acetyl CoA Carboxylase Activity
Obesity is characterized by an increase in the number and size of adipocytes.23
During adipogenesis, the activities of several lipogenic enzymes such as acetyl CoA
carboxylase, fatty acid synthase, and ATP citrate lyase are increased.24 The elevated
regulation of these enzymes suggests they could be targets for anti-obesity agents. It has
been demonstrated recently that mice treated with inhibitors of fatty acid synthase
resulted in decreased food intake and weight loss.25 The hypothesis that acetyl-CoA
carboxylase could be a target for anti-obesity agents was strengthened by a recent study
demonstrating that mice lacking the gene coding for the mitochondrial isoform of acetylCoA carboxylase lost weight despite eating more food.26
A bisubstrate analog inhibitor of carboxyltransferase 6, the component of acetyl
CoA carboxylase, which transfers carbon dioxide from biotin to acetyl CoA to form
malonyl CoA, was synthesized by our collaborators Keith Levert and Grover Waldrop of
Biological Sciences at Louisiana State University.27

Synthesis of this compound

involved attack of the primary sulfur of coenzyme A to displace the chlorine on
compound 3. Since human acetyl CoA carboxylase is now a target for anti-obesity drugs,
the question arose as to whether the bisubstrate analog could inhibit mammalian acetyl
CoA carboxylase and in turn reduce lipid accumulation. Unfortunately, the bisubstrate
analog lacks the hydrophobic character needed to permeate a cell membrane. However,
the chloroacetylated biotin derivative (CABI), or compound 3 is sufficiently hydrophobic
to diffuse across the cell membrane. Although the mechanism is not yet fully understood,
it is believed that CABI is able to permeate the cell membrane via passive diffusion,
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owing to its hydrophobicity. Once inside the cell, 3 reacts with endogenous coenzyme A
to form the bisubstrate analog, compound 6 (Figure 8), and thus inhibits acetyl CoA
carboxylase.
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Figure 8: Bisubstrate analog inhibitor of carboxyltransferase.

To aid in elucidating the mechanism by which CABI reacts with coenzyme A to
inhibit acetyl CoA carboxylase activity, I have synthesized an adduct of CABI (Figure 9).
Compound 7 is obtained in 75% yield via reacting biotin (0.25g, 0.75 mmol, 1 equiv),
Et3N (0.32 mL, 2.24 mmol, 3 equiv), and acetyl chloride (0.081, 1.1 mmol, 1.5 equiv)
under the same conditions employed to produce chloroacetylated compound 3.10 It will
be used to determine if displacement of the chlorine by the primary sulfur of coenzyme A
is the key mechanistic step.
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Figure 9: Structure of CABI adduct that will be utilized for elucidation of the CABI-CoA
mechanism.
Our collaborators also performed a series of inhibition experiments to provide
support for the CABI-CoA hypothesis. To test the ability of CABI to reduce acetyl CoA
carboxylase activity, Levert and Waldrop treated 3T3-L1 preadipocytes with a 10 µM
solution of CABI in DMSO solution or a DMSO control for 4 hours. The whole cell
extracts were prepared and immediately used to measure acetyl CoA carboxylase activity
by analytical reverse phase HPLC. Treatment of preadipocytes with CABI resulted in a
79% reduction of enzyme activity.28 As shown in Figure 10a, the specific activity for
adipocytes treated with DMSO for 4 hours was 1.40 nmol malonyl CoA/min/mg protein.
The activity significantly decreased to 0.30 nmol malonyl CoA/min/mg protein when
3T3-L1 cells were treated with the 10 µM CABI of CABI in DMSO for the same period
of time.
Professor Jackie Stephens, also of the department of Biological Sciences at
Louisiana State University, analyzed the same cytosolic extracts for the expression of
acetyl CoA carboxylase protein levels using streptavidin HRP (Figure 10b).

These

results clearly demonstrate that the reduced activity of acetyl CoA carboxylase is not due
to altered expression levels of the enzyme. In other words, CABI treatment of 3T3-L1
preadipocytes results in decreased acetyl CoA carboxylase activity, but not protein levels,
in isolated cell extracts.
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Figure 10: (A) The specific activity of preadipocytes treated with DMSO (control) or a
10 µM solution of CABI in DMSO. (B) CABI shows no effect on protein levels of
preadipoctytes as measured by streptavidin HRP.
The suggestion that CABI-CoA is formed from the reaction of CABI with
endogenous coenzyme A was further strengthened by the fact that CABI had no effect on
acetyl CoA activity in isolated cellular extracts.27 The bisubstrate analog 6, was indeed
able to inhibit acetyl CoA carboxylase activity when added to isolated cellular extracts in
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vitro. The inhibition constant of CABI-CoA for bacterial acetyl CoA carboxylase was
determined to be 23 µM. Detection of CABI-CoA in extracts treated with CABI would
provide conclusive evidence for the mechanism proposed.

Unfortunately, Levert’s

attempts to isolate the bisubstrate analog have been unsuccessful using HPLC absorption
optics. Waldrop and coworkers have begun studies to detect compound 6 by more
sensitive methods.
3.2 Effect of CABI on Adipogenesis and Lipid Content
In addition to demonstrating that treatment of 3T3-L1 cells with CABI inhibits the
activity of acetyl CoA carboxylase, our collaborators examined the effects of CABI on
the adipogenesis of these cells. Adipogenesis is coincident with expression of several
key transcription factors. To assess the adipocyte differntiation expression, Stephens
analyzed PPARγ (Peroxisome Proliferator Activated Receptors), STAT1, and STAT5A
(Signal Transducers and Activators of Transcription) by Western Blot Analysis.28 All
three markers decreased in cells treated with 17µM and 8µM solutions of CABI in
DMSO (Figure 11). Untreated and control cultures showed no decrease in these markers.
STAT3 is a protein whose expression is not substantially regulated during
differentiation. As shown in Figure 11, the level of STAT3 was not affected by CABI at
any concentration. This observation was significant, because it suggests that CABI is not
acting as a non-specific alkylating agent. Moreover, the fact that the level of acetyl CoA
carboxylase did not decrease with CABI treatment further indicates that CABI is not
exerting a general toxic effect.
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Figure 11: CABI blocks the induction of adipogenic transcription factors in a dose
dependent manner. Whole extracts were prepared one week after induction of
differentiaton in the presence of various doses of CABI, as indicated at the top of the
figure. For each condition, the cells were cultured in the presence or absence of CABI or
DMSO, and the cells were treated every 24 hours. One hundred µg of each extract was
separated by SDS-PAGE, transferred to nitrocellulose, and subjected to Western Blot
Analysis. The molecular mass of each protein is indicated to the left of the blot in
kilodaltons.
Exposure of differentiating adipocytes to 17µM or 8µM solutions of CABI in
DMSO also blocked induction of lipid accumulation in a dose-dependent manner as
measured by Oil red O staining (Figure 12). It should be noted that the inhibition of
CABI was reversible. If the addition of compound 3 was not repeated every 24 hours, the
cells began to differentiate.
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Figure 12: CABI inhibits lipid accumulation in differentiating 3T3-L1 cells. Oil red
O staining was performed on 3T3-L1 cells one week following the induction of
differentiation. Cells were induced to differentiate at 2 days post-confluence and CABI
was replaced with DMEM. The cells were treated every 24 hours with a fresh solution of
CABI or DMSO. Each plate was treated with the following concentrations of CABI: (A)
0 µM, DMSO control; (B) 4 µM; (C) 8 µM; and (D) 17µM.
These results presented by Levert, Waldrop, and Stephens28 are the first
demonstration of a link between a pharmalogical modulation of cytosolic acetyl CoA
carboxylase and inhibition of adipogeneisis. These studies support the gene knockout
experiments in mice, which indicated that acetyl CoA carboxylase is a very promising
target for antiobesity agents.26 The ability of CABI to prevent weight gain in mice fed
high-fat diets is being investigated by biologists at Pennington Biomedical Research
Center. To aid in these experiments, I synthesized 40 grams of compound 3. Currently,
we are searching for alternative solvents and trying to synthesize a more soluble adduct
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for these animal studies. It is our desire to examine the effects of CABI on other types of
cells in which acetyl CoA carboxylase is up-regulated, such as in breast cancer cells.29
3.3 The “RNA World” Hypothesis
For centuries, scientists have been wrestling with the challenge of formulating a
plausible scenario for the origin and early evolution of life. How did a self-replicating
assembly of molecules emerge on early earth and give rise to cellular life?
hypothesis is that early life was based on RNA.30,
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One

That is, the first biocatalysts on

Earth were not made of enzymes but were made of RNA or a very similar polymer.
The appeal of the “RNA World” hypothesis is that catalytic RNA molecules, which
could have served as their own genes, would have been much simpler to duplicate than
proteins. According to this theory, RNA promoted reactions required for life with the
help of metals, pyridines, amino acids, and other small-molecule cofactors. As
metabolism became more complex, RNA developed the ability to synthesize coded
polypeptides that served as more sophisticated cofactors. DNA later replaced RNA as the
genetic polymer, and protein replaced RNA as the prominent biocatalyst.
In a collaborative effort with Professor Anne Grove and Steven Wilkinson of
Biological Sciences at Louisiana State University, we are currently exploring another
aspect of the “RNA World” hypothesis- CO2 fixation. If the early atmosphere was
abundant in carbon dioxide, as many biologists believe, then an RNA molecule(s) that
can catalyze the carboxylation of biotin, the carrier of CO2, would have been essential for
the existence of early life. Typical metabolic reactions involve small molecules that are
not attached to RNA. Demonstrating that RNA can promote interesting reactions using a
tethered substrate is difficult yet important in addressing the question of whether RNA
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can catalyze a reaction involving small compounds. The ability to explore the repertoire
of RNA catalysis dramatically improved with the development of randomization,
selection, and amplification methods.32-34 Ribozymes with new or enhanced activities can
now be isolated from large libraries of ribozyme variants,35-37 and entirely new ribozymes
can be isolated from large pools of random-sequence molecules.38

Figure 13: SELEX process in which BP1 was used for the selection of RNA molecules
that demonstrate the greatest potential to catalyze the carboxylation of biotin.
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Compound 1, which mimics the carboxyphosphate intermediate in the
carboxylation of biotin, is currently being used as a substrate to allow for the selection of
RNA aptamers that likely possess the desired catalytic activity. I synthesized 500 mg of
BP1 using the optimized synthetic and purification conditions previously described. The
final product was submitted to our collaborators to be utilized to generate ribozymes that
catalyze the carboxylation of biotin.
In a selection-amplification process known as SELEX (Systematic Evolution of
Ligands by Exponential Enrichment), a library of RNA aptamers with affinity for BP1
was isolated (Figure 13).

First, BP1 was coupled to an aganose column in aqueous

solution. During pre-selection, those RNA molecules possessing modest affinity for the
tethered substrate were eluted from the column. Next, the RNA aptamers that bound
tightest to the BP1-aganose column were amplified. This selection-amplification process
was repeated until sequences with the desired activity dominated the pool. The ultimate
goal is to screen these RNA sequences for their catalytic capabilities. Grove and
Wilkinson are diligently working to accomplish this task. If we are successful in
discovering a ribozyme(s) that can catalyze the carboxylation of biotin, we will have
extended the known catalytic capabilities of RNA to include CO2 fixation.
3.4 Potential of BP1 As A Potent HIV Protease Inhibitor
Human immunodeficiency virus (HIV) is the causative agent of AIDS (Acquired
Immunodeficiency Syndrome).39 It encodes an aspartic acid protease, HIV PR, whose
function is essential for proper viron assembly and maturation. Inactivation of HIV
protease by either mutation or chemical inhibition leads to the production of immature,
non-infectious viral particles. Thus inhibition of HIV PR is recognized as an important
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therapeutic strategy for treatment of AIDS.40 Structural biochemical methods, nuclear
magnetic resonance, and computational biochemistry are recent additions to the plethora
of approaches used in the rational drug design and discovery process. High-resolution
crystal structures of HIV protease and HIV PR /inhibitor complexes have stimulated the
synthesis of potent protease inhibitors.41

(a)
Figure 14: (a) Molecular model of BP1 (green) bound to the active site of HIV protease.
(b) Position of BP1 in the flaps of the aspartic protease and its relation to Asp25/25’ and
Ile50/50’
(Fig. con'd.)
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The experimental crystal structure of recombinant native HIV PR was first
reported by scientists from Merck.42 While studies initially disagreed about certain
details of the structure, they all confirmed that HIV protease is a homodimer and that the
active site closely resembles that of other known aspartic proteases.41 Figure 14a shows
BP1 bound to the active site of the aspartic acid protease. Generation of this molecular
model inspired us to explore the inhibitory effect of compound 1 on HIV PR.
Preliminary experiments were performed by Dr. Lui Marzilli, Chairman of the
Department of Chemistry at Louisiana State University.

He reported minimal

inactivation of HIV PR by compound 1. Nevertheless, the reaction intermediate analog
possesses several functional features that have been proven essential for the design of
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effective protease inhibitors: a cyclic urea moiety, symmetry or pseudosymmetry, and a
biotin scaffold. Hence, we believe, BP1 remains a strong anti-HIV drug candidate.
The two halves of HIV protease are topologically related by an approximate
intramolecular C2-axis. Each monomer consists of 99 amino acid residues. The active
site triad (Asp25, Thr26, Gly27) is located in a loop whose structure is stabilized by a
network of hydrogen bonds. The flap, which consists of residues 45-55, is a β hairpin
that covers the catalytic site and participates in the binding of inhibitors and substrates.
Crystal structures indicate that interactions of molecules with Asp25/25’ and Ile50/50’
are particularly critical for high affinity and specificity for the viral protease.
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Figure 15: DMP323, a potent symmetrical HIV protease inhibitor developed by DuPont
Merck.
In 1993, the DuPont Merck group succeeded in the development of a potent
nonpeptide orally bioavailable HIV protease inhibitor, DMP32343 (Figure 15). Design of
this subnanomolar inhibitor was based on careful inspection of the high-resolution of Xray structures available for HIV protease-inhibitor complexes.44

In all of these

complexes, the backbone amide hydrogens of Ile 50 and 50’ in the flaps of the enzyme
are hydrogen bonded to the carbonyl oxygen of the inhibitors through a tetra-coordinated
H2O molecule.44 This H2O molecule is considered to play a critical role in closing the
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“flaps” over the protease inhibitor and its presence has not been observed in mammalian
aspartic proteases. The rationale underlying the development of DMP323 was to displace
the H2O molecule by the cyclic urea carbonyl oxygen.

Indeed the conserved H2O

molecule was not seen in the HIV protease-DMP323 crystal structure.43 The structure of
the protease/DMP323 complex reveals many stabilizing protein-ligand interactions. It
shows that the carbonyl oxygens of the catalytic aspartic residues, Asp 25,25’, and the
diol oxygens of the inhibitor are positioned to form a network of hydrogen bonds.
A magnified representation of the BP1-HIV PR complex (Figure 14b) shows the
sites of interaction between compound 1 and the flap residues of the aspartic protease.
Although energy minimization studies have not been performed, I believe that the cyclic
urea oxygen of BP1 is similarly positioned to perform the important role of accepting two
hydrogen bonds from the Ile residues. In fact, I propose that the modest inhibition
reported by Marzilli is most attributed to this interaction. Understanding the relationship
of BP1 to Asp 25 and 25’, which is less apparent from Figure 14b, is very likely the key
to improving activity.
Initially, I concluded that the lack of activity of BP1 was directly related to the
geometry of the compound. However, recent studies revealed that the symmetry of the
HIV protease dimer has guided the design of twofold and pseudosymmetric
compounds.45 Kempf et al demonstrated that high oral bioavailability can be achieved
with pseudosymmetric molecules.46 One such compound, A-7703 (Figure 16) possessed
sufficient aqueous solubility for intravenous administration47 and was examined in
clinical trials (unpublished results). In the search for related inhibitors with improved
bioavailability, A-80987 was produced. It retained submicromolar antiviral activity.
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More importantly, this potent inhibition was accompanied by significant oral
bioavailability in three animal species and in humans. Intense study of a series of A80987 analogues has now yielded valuable insight into the relationship of chemical
structure to antiviral activity, aqueous solubility, and hepatic metabolism. Application of
these insights to compound design culminated in the discovery of ABT-538 (Figure 16),
an HIV protease inhibitor with enhanced antiviral activity and exceptional oral
pharmacokinetics.
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Figure 16: Structures of pseudosymmetric bioavailable HIV protease inhibitors.
The X-ray structure of the streptavidin-biotin complex revealed the importance of
the urea oxygen of (+)-biotin as a superior hydrogen-bond acceptor.47 The excellent
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hydrogen bond accepting ability of urea was the reason Han and coworkers incorporated
this functional group into their cyclic urea series of HIV PR inhibitors.43,

49

It later

occurred to them that (+)-biotin, composed of two cis-fused five-membered rings with
the important urea group, could be used as a scaffold for synthesizing anti-HIV
compounds. Modeling suggested that the (+)-biotin derivatives can fit into the binding
site of the protease, as demonstrated by the BP1-HIV PR complex. (Figure 14a). In
addition, the sulfur atom in (+)-biotin may form a weak hydrogen bond with the aspartic
acid residues (25 and 25’).50 Han recently reported preliminary results of the synthesis
and biological activities of biotin-derived HIV PR inhibitors.51

They succeeded in

developing a new class of compounds with good transitions from Ki to antiviral IC90
values. The most potent inhibitor of this series, shown in Figure 21, has Ki of 0.5 µM
and an IC90 of 7 µM.
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Figure 17: Structure of the potent active HIV protease inhibitor from of a new class of
biotin-derived compounds.
In recent years, scientists have reported the design and synthesis of high-affinity
bioavailable inhibitors that lack a C2 axis as well as potent anti-HIV compounds that
possess a biotin scaffold. Hence, I conclude that the modest activity exhibited by our
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pseudosymmetric biotin-derived analog (1) is a matter of size rather than geometry or
functionality.

I am convinced that extended substitution of the valeric acid and

phosphonic acid side chains of BP1 will position the carbonyl oxygens closer to those of
the flap residues Asp 25 and 25’. As a result, a stronger network of hydrogen bonds will
be formed, which is essential to the stabilization of the inhibitor/protease complex.
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Chapter Four
Biotin-Derived Chiral Cationic Polymeric Surfactant
4.1 Introduction
The separation of enantiomeric mixtures into individual optical isomers is one of
the most challenging issues in analytical chemistry. Development of new methodologies
for improved chiral separation is recognized as an important achievement by researchers
in many areas of science, particularly, the pharmaceutical and agricultural industries. In
the former case, many drugs are chiral and therefore the design of and synthesis of these
compounds often involve a racemic mixture rather than a pure form of the drug. The
problem is that one form of a racemic mixture may have a medicinal application while
the other enantiomer may be very toxic, as in the case of thalidomide.52 These
observations have resulted in the recent release of new FDA guidelines regulating the
marketing of chiral drugs. Such regulation has influenced the potential growth in the
chirotechnology industry, specifically in the area of chiral drug separations.53
Early attempts to separate racemic mixtures into individual enantiomers employed
naturally occurring chiral materials, such as wool54,55 and cellulose or other
polysaccharides,56 in conjunction with standard separation methods.

These early

strategies of the 1920’s provided some degree of success for separation of racemic
mixtures.

However, isolations employing naturally occurring compounds are often

complicated by their poor mechanical and chromatographic behavior.
Recent studies have demonstrated the use of chiral micelles as a viable alternative
for achieving enantioselective separations. These studies have been performed primarily
by use of capillary electrophoresis,57,58 more specifically micellar electrokinetic
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chromatography (MEKC). In chiral recognition by this method, the micelles themselves
can become the major site of interaction, or they can incorporate various chiral selectors
which are added to the separation medium. Even these systems are limited in their
applications. One major problem encountered with the use of normal micelles in MEKC
is that the interactions of many analytes with these micelles are often too strong to allow
adequate discrimination.

Warner and coworkers previously hypothesized that a

polymeric surfactant will have stronger chiral recognition properties than conventional
(non-polymerized) chiral micelles.
Professor Isiah Warner has dedicated the past five years of his career to offering
unique possibilities for chiral separations. During this time, the Warner research group
has made significant advances and contributions to the scientific literature in this area of
analytical chemistry.

Currently, the specific aim of his research is to examine the

structural parameters that may contribute to the enhanced chiral recognition using
polymeric surfactants rather than micelles. The Warner and Strongin research groups
will collaboratively assess the effect of polar head group type on the utility of the
polymeric surfactant as a stationary phase in MEKC.
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Figure 18: Structure of biotin-derived chiral cationic monomer.
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The type of head group can provide drastic differences in the properties of the
polymeric surfactant and thus in the elution window in the MEKC process. To date,
Warner et al. have only explored chiral head groups which are derivatives of amino acids.
Previous experiments have shown that these anionic surfactants have particular
appreciation for separation of cationic and neutral analytes. However, there has been
some difficulty with separation of anionic analytes. It is believed that this is related to
charge repulsion between the analyte and the highly anionic chiral polymeric surfactant.
Therefore, a logical extention of the current research is to evaluate cationic polymeric
surfactants. To this end, we describe the synthesis of compound 8, a new chiral cationic
biotion-derived monomer (Figure 18).
4.2 Synthesis of Biotin-Derived Chiral Cationic Monomer
The synthesis of 8 (Scheme 4) begins with the transformation of (+)-biotin to the
corresponding undecylenyl ester in 52% via stirring DMF (40 mL), biotin (1.0 g, 4.1
mmol, 1 equiv), undecylenyl alcohol (1.02 mL, 5.11 mmol, 1.25 equiv), DMAP (0.05 g,
0.41 mmol, 0.1 equiv), HOBT (0.06 g, 0.41 mmol, 0.1 equiv), and DCC (0.93 g, 4.5
mmol, 1.1 equiv) at rt for 12 h. Chloroacetylated compound 9 was obtained by two
different synthetic methods. The first procedure is based on Amspacher’s published
procudure for highly regioselective acylation of biotin esters.10 Chloride 10 is afforded in
59% yield by careful dropwise addition of Et3N (0.69 mL, 4.9 mmol, 3 equiv) and
chloroacetylchloride (0.39 mL, 2.5 mmol, 1.5 equiv) in three portions (0.5 equiv every 12
h) to a solution of biotin undecylenyl ester (0.65 g, 1.6 mmol, 1 equiv) in CH2Cl2 at –78
°C; then the solution is warmed to rt. The alternative procedure was derived by Tanaji
Talele, a post doc at Louisiana State University. This method involves stirring of ester 9

35

(0.85 g, 2.14 mmol, 1 equiv) in chloroacetylchloride (8.5 mL, neat) at 65 °C for 3 h.
Compound 10 is obtained in 24% yield. This is a 50% decrease in the yield afforded by
the original method. Although we have not yet optimized these conditions, the advantage
of the new method is a rapid conversion time of several hours as opposed to 2 days.
Subsequently, allowing 10 (0.45g, 0.95 mmol, 1 equiv) to stir in pyridine (5 mL, neat) at
rt for 12 hr results in a 41% yield (13% overall yield) of the biotin-derived chiral cationic
monomer.
O
HN
H

DCC

NH
H

OH

S

HO

DMAP
HOBT
52%

O
(+) - biotin
O

HN
H

O
NH
H

Cl

Cl
O

S

Et3N

O

59%

9
O

O
Cl

N

NH
H

H

N
O

S

41%

O
10

O

O
N

N

NH
H

H
S

O
O
8

Scheme 4: Preparation of chiral cationic monomer from (+)-biotin.
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Chapter Five
Conclusion
5.1 Future Work
5.1.1 A New Synthetic Route to Carboxyphosphate Reaction Intermediate 1
In our efforts to improve the yield of the conversion of 5 to 1 (Scheme 3), it
occurred to us that an alternative route to target compound 1 may be via a synthetic
pathway which eliminates the saponification step completely. (Scheme 5). This method
would reduce the number of steps required for the total transformation of (+)-biotin to
BP1 from four to six.

Chloroacetylated compound 11 has been synthesized and

characterized by 1H NMR and mass spectrometry. (+)-Biotin (1.00 g, 0.409 mmol, 1
equiv) and chloroacetylchloride (10 mL, neat) were stirred at 65 °C for 5 hr to obtain 11
in 14% yield. The formation of phosphonate ester 12 has been confirmed by 1H NMR as
well, however, further purification is required. Currently, the specific aim of our research
is to produce BP1 directly from the hydrolysis of unprotected compound 12. Upon
achieving this goal, the next task will be to fully characterize all intermediates and
increase the efficiency of the modified synthesis.
5.1.2 Multisubstrate and Transition State Analogs
The current work in this area focuses on attachment of adenosine moieties to the
1’-N of (+)-biotin to form the structure(s) shown in Figure 5. Two strategies are currently
being employed. The first method involves coupling of CABI (3) to the thio-derivatives
AMP, ADP, ATP to form the corresponding multisubstrate analog (Scheme 6). The
second procedure entails two reactions.

Compound 3 first undergoes an Arbuzov

reaction to form a ethylchlorophosphonate adduct.58 This product is then reacted with the
adenosine salt59,60 to form the desired multisubstrate analog61 (Scheme 7). Further work
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on these schemes is required; therefore, yields have not been reported.

We are

researching the most efficient synthetic and analytical conditions that will provide us with
these compounds in greatest yield.
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Scheme 5: Alternative route to compound 1 from (+)-biotin.
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Work in progress also includes the design and synthesis of transitions state
analogs to complement our reaction intermediate analog work (Figure 19). The
development of these compounds may be applicable to our collaborative research project
with Professor Anne Grove to support the “RNA World” hypothesis. Isolation of RNA
aptamers based on their ability to bind transition-state analogs is a current approach to the
conversion of ribozymes to forms that use free small-molecule substrates.62,63
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Figure 19: Stuctures of proposed transition state analogs.
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The development of analogs 19a and 19c is premature.The reaction conditions by
which these compound will be synthesized are still being investigated. In contrast, an
efficient route to transition state analog 19b has been derived (Scheme 8). The 1H NMR
spectrum of the crude reaction mixture indicated that the desired compound was
produced. Because the compound was not pure, the percent yield was not determined. In
addition, mass spectrometry generated a peak at 443.2 (calculated 442.55). A mass peak
of 459.4 was recorded as well. The calculated mass of the oxidized by-product is 458.6
g/mole.

The ratio of this peak to the former was approximately 9:1. Future work

includes optimizing reaction conditions that will decrease the amount of side product
formed. for sulfonate transition-state analog 19b. We will also investigate the best
analytical method for isolating the two products.
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Scheme 8: Preparation of transition state analog 19b from (+)-biotin.

5.2 Conclusion
In conclusion we have demonstrated the potential of reaction intermediate analog 1
and and other biotin derivatives in several areas. We have synthesized and studied BP1
and analogs for inhibition of HIV protease and acetyl CoA carboxylase as well as began
the screening for ribozyme activity. We have synthesized CABI for in vitro adipogenesis
and lipid content studies. These results have led to scale up of the CABI synthesis for
anitobesity studies in mice. The synthesis of multsubstrate and trasition state analogs is
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ongoing. These compunds could serve as leads to a series of more potent inhibitors,
based on biotin carboxylase’s role in fatty acid synthesis. The transition state analags
may be especially useful in the selection-amplification process employed in ribozyme
screening. We have also synthesized a chiral cationic monomer that will be utilized to
provide alternative methods for analytical chiral separations.
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Chapter Six
Experimental
6.1 Materials and Methods
Biotin was purchased from Bioworld. All other reagents were purchased from
Sigma or Aldrich. All nonaqueous reactions were carried out under N2 or Ar in flame
dried glassware. CH2Cl2 and TMSBr were distilled over CaH2. Anhydrous DMF and
pyridine were purchased from Aldrich. Analytical thin-layer chromatography (TLC) was
performed using general purpose 60-Å silical gel on glass (Aldrich). TLC plates were
visualized with aqueous KMnO4 or I2. Chromatography columns were packed with
Kieselgel 60-Å silica gel 230-400 mesh (Sorbent Technologies). Proton (1H) and carbon
(13C) NMR spectra were generated on a Bruker ARX400, 400 MHz and a Bruker
ARX250, 250 MHz spectrometer. IR spectra were recorded on a Nicolet 320 FT-IR
spectrometer. High-resolution mass spectrometry was provided by the Louisiana State
University Mass Spectrometry Facility; spectra were recorded on a Finnigan MAT 900
with a PATRIC detector.
6.2 Experimental Procedures
6.2.1 Purification of 5-(6,8-diaza-7-oxo-6-(2-phosphonoacetyl)-3-thiabicyclo[3.3.0]
oct-2-yl) pentanoic acid 1
For reverse phase HPLC analysis a C-18 column (Dynamax 60 Å, C18 83-221-C)
was used as a stationary phase. The mobile phase was changed from 100% H2O to 100%
MeOH over a 30 minute time period. Flow rate was 5 mL/min. MeOH was removed in
vacuo and the remaining filtrate was lyophilized.

42

6.2.2 Benzyl 5-[(3aS,4S,6aR)-1-acetyl-3-oxohexahydro-1H-thieno[3,4-d]imidazol-4yl]pentanoate 7
Benzyl ester 2 (0.25 g, 0.75 mmol) and Et3N (0.32 mL, 2.24 mmol) are added to
10 mL of CH2Cl2. Acetylchloride (0.081 mL, 1.1 mmol) is added in three portions. The
mixture is stirred and brought to –78 °C; then acetylchloride (0.027 mL, 0.37 mmol) is
added. The mixture is stirred for 12 hours and allowed to warm to room temperature.
This series of steps is repeated 2 more times. The reaction mixture is filtered and the
filtrate is evaporated in vacuo. Then the resultant thick brownish oil is dissolved in
CH2Cl2, absorbed on to silica, and purified by column chromatography. A solution of
4% MeOH, 48% hexane, and 48% EtOAc is used as the mobile phase to afford a
yellowish oil (0.21 g, 75%). 1H NMR (DMSO-d6) δ 7.90 (s, 1H), 7.35 (s, 5H), 5.08 (s,
2H), 4.75 (m, 1H), 4.12 (m, 1H), 3.29 (m, 1H), 2.95-2.85 (m, 2H), 2.49 (t, J = 7.2 Hz,
2H), 2.34 (s, 3H), 1.72-1.25 (m, 6H);

13

C NMR (DMSO-d6) δ 173.58, 170.22, 157.04,

137.14, 129.30, 128.85, 66.20, 61.85, 57.95, 55.58, 34.48, 34.11, 28.84, 25.26, 24.32; IR
(thin film) 3252, 3131, 2936, 1684, 1375, 1251, 755, 699, 632; HRMS: found 377.40,
calculated 376.47.
6.2.3 Undec-10-enyl 5-[3aS, 4S, 6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4yl]pentanoate 9
(+)-Biotin (1.00 g, 4.09 mmol), undecylenyl alcohol (1.02 mL, 5.11 mmol),
DMAP (0.05g, 0.409 mmol), and HOBT (0.055 g, 0.409 mmol) are added to a 40 mL of
DMF in a 250 mL 3-neck round bottom flask. The mixture is mildly heated while
stirring until a homogeneous solution of reagents is achieved. DCC (0.93 g, 4.5 mmol) is
added; then the reaction mixture is allowed to stir at room temperature for 12 hours. The
reaction mixture is filtered and the filtrate was concentrated in vacuo. The resultant solid
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is dissolved in CH2Cl2 and extracted three times with H2O. The organic layer is dried
over MgSO4 and filtered. The organic filtrate is concentrated and the pale yellow solid is
purified by flash chromatography with 5% MeOH, 95% EtOAc to obtain a white solid 9
in 52% yield. 1H NMR (DMSO-d6) δ 6.42 (s, 1H), 6.35 (s, 1H), 5.74 (m,1H), 5.02-4.91
(m, 2H), 4.35 (m, 1H), 4.11 (m, 1H), 3.98 (t, J = 7.3 Hz, 2H), 2.01 (m 2H), 2.87-2.51 (m,
2H), 1.51-1.25 (m, 20H); 13C NMR (DMSO-d6) δ 173.75, 163.56, 139.70, 115.52, 76.09,
64.54, 61.90, 60.04, 56.23, 34.05, 29.75, 29.48, 29.35, 29.13, 28.99, 28.88, 26.24, 25.43;
IR (KBr) 3257, 2918, 2815, 1710, 1731, 1473, 1422, 1267, 1178, 901, 731, 658; HRMS:
found 397.32, calculated 396.59

Figure 20: 1H NMR spectrum of 7.
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Figure 21: Carbon 13 spectrum of 7.

Figure 22: 1H NMR spectrum of 9.
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Figure 23: COSY NMR spectrum of 9.
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Figure 24: Carbon 13 NMR spectrum of 9.

6.2.4 Undec-10-enyl 5-[3aS,4S,6aR)-1-(chloroacetyl)-2-oxohexahydro-1H-thieno[3,4d]imidazol-4-yl]pentanoate 10
Undecylenyl ester 9 (0.65g, 1.64 mmol) and Et3N (0.69 mL, 4.92 mmol) are
added to 20 mL of CH2Cl2. Chloroacetylchloride (0.39 mL, 2.46 mmol) is added in three
portions. The reaction mixture is stirred at –78 °C and chloroacetylchloride (0.065 mL,
0.82 mmol) is added to the flask. The solution is allowed to stir at room temperature for
12 hours. This sequence of steps is repeated two more times. The crude reaction mixture
was evaporated in vacuo and the resultant light brown oil is dissolved in CH2Cl2 and
purified by flash chromatography with 4% MeOH, 48% EtOAc, 48% hexane. A yellow
oil is furnished in 59% yield. Via an alternative method, compound 9 (0.85 g, 2.14
mmol) is added to chloroacetylchloride (0.85 mL, neat). The reaction mixture is allowed
to stir at 65 °C for 3 hours. The solution is allowed to warn to room temperature then
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diluted with CH2Cl2. While stirring, H2O was carefully added over 3 minutes. Then the
organic phase is washed twice more with H2O and once with concentrated NaHCO3. The
CH2Cl2 layer is dried over MgSO4 then filtered. The filtrate is evaporated in vacuo. The
resultant yellow oil is dissolved in 4% MeOH 48% hexane 48% EtOAc and purified by
column chromatography with the same solvent system. A yellow solid is afforded in 24
% yield. 1H NMR (DMSO-d6) δ 8.09 (s, 1H), 5.77 (m ,1H), 5.01-4.90 (m, 2H), 4.79 (m,
3H), 4.18 (m, 1H), 3.98 (t, J = 6.5 Hz, 2H), 3.13 (m, 1H), 3.03-2.87 (m, 2H), 2.28 (t, J =
7.3 Hz, 2H), 2.01 (m, 2H), 1.68-1.24 (m, 20H); 13C NMR (DMSO-d6) δ 173.72, 166.32,
156.65, 139.69, 115.53, 64.56, 62.21, 58.87, 55.46, 44.84, 34.05, 29.76, 29.65, 29.49,
29.36, 29.13, 29.01, 28.85, 26.24, 25.31; IR (KBr) 3346, 2927, 2855, 1740, 1700, 1394,
1234, 1100, 795; HRMS: found 473.32, calculated 473.07.

Figure 25: 1H NMR spectrum of 10.
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Figure 26: Carbon 13 NMR spectrum of 10.

Figure 27: 1H NMR spectrum of 8.
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Figure 28: Carbon 13 NMR of spectrum of 8.
6.2.5 xo-2-{(3aS,4S,6aR)-2-oxo-4-[5-oxo-5-(undec-10-enyloxy) pentyl]hexahydro-1Hthieno[3,4-d]imidazol-1-yl}ethyl)pyridinium 8
Chloracetylated compound 10 (0.45 g, 0.95 mmol) is allowed to stir in pyridine (5
mL, neat) at room temperature for 12 hours. The reaction mixture is concentrated in
vacuo.

The resultant yellow oil was dissolved in CH2Cl2 and purified by column

chromatography in 10% MeOH 90% CH2Cl2 to afford a yellow solid in 41% yield.

1

H

NMR (DMSO-d6) δ 9.0 (m, 2H), 8.75 (m, 1H), 8.43 (s, 1H), 8.31 (m, 2H), 6.0 (m, 2H),
5.80 (m, 1H), 5.01-4.83 (m, 2H), 4.78 (m, 1H), 4.30 (m, 1H), 3.99 (t, J = 6.5 Hz, 2H),
3.15 (m, 1H), 2.98-2.87 (m, 2H), 2.30 (t, J = 7.3 Hz, 2H), 1.95 (m, 2H), 1.64-1.25 (m,
20H);

13

C NMR (DMSO-d6) δ 173.73, 165.93, 156.74, 147.40, 139.68, 128.30, 115.52,

76.12, 64.56, 62.00, 59.48, 55.45, 34.05, 29.74, 29.64, 29.49, 29.36, 29.13, 29.00, 26.24,
25.31; IR (KBr) 3206, 3078, 2922, 2854, 1743, 175, 1653, 1634, 1327, 1254, 1187, 851,
768, 690; HRMS: found 516.41, calculated 516.40.
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6.2.6 5-[3aS,4S,6aR)-1-(chloroacetyl)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4yl]pentanoic acid 11
(+)-Biotin (1.00 g, 0.409 mmol) was added to chloroacetylchloride (10 mL, neat)
in a 50 mL round bottom flask. The reaction mixture was allowed to stir at 65 °C for 5
hours. The chloraocetylchloride was removed by vacuum distillation. The resultant
milky suspension was dissolved in CH2Cl2 and washed three times with H2O and once
with saturated NaHCO3. The organic layer was dried over MgSO4. The solid was
purified by column chromatography using 10% MeOH 90% EtOAc mobile phase to
obtain a white solid in 15% yield.

1

H NMR (DMSO-d6) δ 8.10 (s, 1H), 4.79 (m, 3H),

4.31 (m, 1H), 3.32 (m, 1H), 3.04-2.79 (m, 2H), 2.18 (t, J = 7.3 Hz, 2H), 1.78-1.23 (m,
6H); HRMS: found 321.3, calculated 320.79

Figure 29: 1H NMR spectrum of 11.
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